DB:PUL

Stock Analysis Report

Executive Summary

Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors worldwide.


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

Share Price & News

How has Biosearch's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PUL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

15.2%

PUL

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-36.6%

PUL

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: PUL underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: PUL underperformed the German Market which returned -17.7% over the past year.


Shareholder returns

PULIndustryMarket
7 Day15.2%11.2%7.3%
30 Day-30.7%-5.3%-17.9%
90 Day-23.5%-21.9%-25.8%
1 Year-36.6%-36.6%-4.9%-5.1%-15.1%-17.7%
3 Yearn/a17.7%16.5%-18.7%-25.6%
5 Yearn/a-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is Biosearch's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Biosearch undervalued compared to its fair value and its price relative to the market?

80x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: PUL (€0.77) is trading above our estimate of fair value (€0.38)

Significantly Below Fair Value: PUL is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PUL is poor value based on its PE Ratio (80x) compared to the Biotechs industry average (34x).

PE vs Market: PUL is poor value based on its PE Ratio (80x) compared to the German market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: PUL is poor value based on its PEG Ratio (1.1x)


Price to Book Ratio

PB vs Industry: PUL is good value based on its PB Ratio (1.9x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Biosearch forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

74.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PUL's forecast earnings growth (74.1% per year) is above the savings rate (-0.4%).

Earnings vs Market: PUL's earnings (74.1% per year) are forecast to grow faster than the German market (14.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PUL's revenue (17% per year) is forecast to grow faster than the German market (4.1% per year).

High Growth Revenue: PUL's revenue (17% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PUL's Return on Equity is forecast to be low in 3 years time (16.2%).


Next Steps

Past Performance

How has Biosearch performed over the past 5 years?

46.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PUL has high quality earnings.

Growing Profit Margin: PUL's current net profit margins (2.8%) are lower than last year (12.3%).


Past Earnings Growth Analysis

Earnings Trend: PUL has become profitable over the past 5 years, growing earnings by 46.4% per year.

Accelerating Growth: PUL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PUL had negative earnings growth (-81%) over the past year, making it difficult to compare to the Biotechs industry average (8.7%).


Return on Equity

High ROE: PUL's Return on Equity (2.7%) is considered low.


Next Steps

Financial Health

How is Biosearch's financial position?


Financial Position Analysis

Short Term Liabilities: PUL's short term assets (€17.4M) exceed its short term liabilities (€6.0M).

Long Term Liabilities: PUL's short term assets (€17.4M) exceed its long term liabilities (€3.6M).


Debt to Equity History and Analysis

Debt Level: PUL's debt to equity ratio (18.5%) is considered satisfactory.

Reducing Debt: PUL's debt to equity ratio has reduced from 46.7% to 18.5% over the past 5 years.

Debt Coverage: PUL's debt is well covered by operating cash flow (28.4%).

Interest Coverage: PUL's interest payments on its debt are well covered by EBIT (12.3x coverage).


Balance Sheet

Inventory Level: PUL has a high level of physical assets or inventory.

Debt Coverage by Assets: PUL's debt is covered by short term assets (assets are 4x debt).


Next Steps

Dividend

What is Biosearch's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PUL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PUL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PUL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PUL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PUL's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.8yrs

Average board tenure


CEO

José María Roset Monrós

no data

Tenure

Mr. José María Roset Monros serves as the Chief Executive Officer of Biosearch SA (alternate name: Puleva Biotech SA) and served as its General Director. Mr. Monros served as the Chief Financial Officer of ...


Board Members

NamePositionTenureCompensationOwnership
Erick Boutry
Proprietary Member of the Board of Directors9.17yrs€1.00kno data
Isidoro Martínez de la Escalera Álvarez
Independent Member of the Board of Directors7.75yrs€34.00k0.071% 32.3k
José Cerezuela Rodríguez
Proprietary Member of the Board of Directors7.75yrs€5.00kno data
Jesus Del Hoyo Cabetas
Independent Member of the Board of Directors3yrsno datano data
Ignacio Elola Zaragueta
President of the Board of Directorsno datano datano data

7.8yrs

Average Tenure

Experienced Board: PUL's board of directors are considered experienced (7.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.2%.


Top Shareholders

Company Information

Biosearch, S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biosearch, S.A.
  • Ticker: PUL
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €45.756m
  • Shares outstanding: 57.19m
  • Website: https://www.biosearchlife.es

Number of Employees


Location

  • Biosearch, S.A.
  • Camino de Purchil, 66
  • Granada
  • 18004
  • Spain

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOBME (Bolsas y Mercados Espanoles)YesCommon StockESEURDec 2001
0MZVLSE (London Stock Exchange)YesCommon StockGBEURDec 2001
BIOEBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBEURDec 2001
PULDB (Deutsche Boerse AG)YesCommon StockDEEURDec 2001

Biography

Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors worldwide. It offers a portfolio of approximately 200 products in lipids, probiotics, and botanical extracts. The company provides a range of probiotics isolated from human breast milk under the Hereditum brand for use in infant nutrition, gastrointestinal health, and immune system and prevention of infections. It also offers various eicosapentaenoic acid and docosahexaenoic acid rich ingredients under the Eupoly-3 name, which consists of oils, emulsions, and micro-encapsulated powder for functional foods, primarily dairy products, baby foods, medical foods, and food supplements. In addition, the company provides dry, fluid, glycerinated, and soft extracts under the Exxentia name. Biosearch, S.A. is headquartered in Granada, Spain. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 01:04
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.